Skip to main content

Table 2 Post-COVID-19 symptoms at week 4

From: Impact of COVID-19 and effects of BNT162b2 on patient-reported outcomes: quality of life, symptoms, and work productivity among US adult outpatients

Symptom

All

BNT162b2

Unvaccinated

P valuea

General symptoms

 Tiredness or fatigue

136 (41.2%)

71 (40.6%)

65 (41.9%)

0.802

 Symptoms that get worse after physical or mental ctivities

50 (15.2%)

18 (10.3%)

32 (20.6%)

0.009

 Fever

1 (0.3%)

0 (0.0%)

1 (0.7%)

0.470

 General pain/discomfort

50 (15.2%)

20 (11.4%)

30 (19.4%)

0.045

Respiratory and cardiac

 Difficulty breathing or shortness of breath

58 (17.6%)

26 (14.9%)

32 (20.6%)

0.168

 Cough

86 (26.1%)

40 (22.9%)

46 (29.7%)

0.159

 Chest or stomach pain

32 (9.7%)

14 (8.0%)

18 (11.6%)

0.268

 Fast-beating or pounding heart (also known as heart palpitations)

38 (11.5%)

17 (9.7%)

21 (13.5%)

0.276

Neurologic

 Change in smell or taste

51 (15.5%)

19 (10.9%)

32 (20.6%)

0.014

 Headache

67 (20.3%)

28 (16.0%)

39 (25.2%)

0.039

 Dizziness on standing (lightheadedness)

45 (13.6%)

20 (11.4%)

25 (16.1%)

0.214

 Difficulty thinking or concentrating (sometimes referred to as “brain fog”)

86 (26.1%)

43 (24.6%)

43 (27.7%)

0.513

 Pins-and-needles feeling

24 (7.3%)

10 (5.7%)

14 (9.0%)

0.247

 Sleep problems

81 (24.5%)

35 (20.0%)

46 (29.7%)

0.042

 Mood changes

36 (10.9%)

13 (7.4%)

23 (14.8%)

0.031

 Memory loss

38 (11.5%)

11 (6.3%)

27 (17.4%)

0.002

Other

 Diarrhea

23 (7.0%)

6 (3.4%)

17 (11.0%)

0.007

 Joint or muscle pain

67 (20.3%)

29 (16.6%)

38 (24.5%)

0.073

 Rash

11 (3.3%)

3 (1.7%)

8 (5.2%)

0.082

 Changes in period cycles

28 (11.5%)

12 (9.4%)

16 (13.8%)

0.280

Number of post-COVID-19 symptoms, mean (SD)

3.1 (3.6)

2.5 (3.0)

3.7 (4.1)

0.002

 0

100 (30.3%)

54 (30.9%)

46 (29.7%)

0.001

 1–2

100 (30.3%)

59 (33.7%)

41 (26.5%)

 

 3–5

61 (18.5%)

40 (22.9%)

21 (13.5%)

 

 6–8

32 (9.7%)

9 (5.1%)

23 (14.8%)

 

 ≥ 9

37 (11.2%)

13 (7.4%)

24 (15.5%)

 
  1. aP-values of t-test for number of symptoms, chi-square or Fisher’s exact tests when any one cell has an expected frequency less than 5 for individual symptoms and number of symptom category comparing the BNT162b2 cohort and the unvaccinated cohort